Market Place
Sourcing Support
KEYTRUDA Plus LENVIMA With TACE Improves PFS In Liver Cancer
14 Sep 2024 //
BUSINESSWIRE
Medivir To Present Fostrox + Lenvima Data At ESMO And Host Webcast
12 Sep 2024 //
PR NEWSWIRE
Eisai To Present E7386 At ESMO Annual Meeting
08 Sep 2024 //
PR NEWSWIRE
Medivir To Present Fostrox + Lenvima HCC Data At ESMO Conference
18 Jul 2024 //
PR NEWSWIRE
New Efficacy Data for Non-Clear Cell RCC a From KEYNOTE-B61 Added to LENVIMA
27 Jun 2024 //
PR NEWSWIRE
New Analysis From Phase 3 REFLECT Trial On LENVIMA At ESMO GI 2024
27 Jun 2024 //
PR NEWSWIRE
BMS: Opdivo+Yervoy Improved Overall Survival Vs Lenvatinib/Sorafenib
04 Jun 2024 //
BUSINESSWIRE
Merck`s endometrial cancer therapy fails trial
10 May 2024 //
REUTERS
Akeso Presented Promising Results of Cadonilimab and Lenvatinib
23 Jan 2024 //
PR NEWSWIRE
Fostrox + Lenvima shows improved rates to progression in advanced liver cancer
17 Jan 2024 //
PR NEWSWIRE
Merck-Eisai`s endometrial cancer therapy combo fails first-line treatment trial
09 Dec 2023 //
REUTERS
Merck and Eisai`s cancer combo flops 2 more trials
23 Sep 2023 //
FIERCE PHARMA
Medivir reports promising interim data
04 Sep 2023 //
PR NEWSWIRE
Merck and Eisai to stop Keytruda plus Lenvima trial in head and neck cancer
26 Aug 2023 //
ENDPTS
OS Data Confirm Pembrolizumab/Lenvatinib as a Frontline Option in Advanced RCC
08 Jul 2023 //
ONCLIVE
Shilpa Medicare launches Lenvatinib Capsules in India under the brand Lenshil
30 Jun 2023 //
INDIAN PHARMA POST
Merck, Eisai to discontinue late-stage study for skin cancer
08 Apr 2023 //
BUSINESSWIRE
First patient dosed in Ph 2a part of Medivir`s study with fostrox with Lenvima
14 Mar 2023 //
PR NEWSWIRE
Medivir has completed a successful pre-IND meeting with the FDA
12 Dec 2022 //
PRNEWSWIRE
Eisai Announces Evidence on the Clinical Effectiveness of LENVIMA Monotherapy
21 Oct 2022 //
PRNEWSWIRE
Scotland backs three new uses for MSD’s Keytruda
11 Oct 2022 //
PHARMAPHORUM
Merck & Eisai Present Results From PIII LEAP-002 Trial
10 Sep 2022 //
BUSINESSWIRE
Positive appraisal for Eisai’s Kisplyx in combination with MSD’s Keytruda
19 Aug 2022 //
PHARMA TIMES
Regeneron expects approval delay of Libtayo plus chemo in NSCLC
04 Aug 2022 //
FIERCEPHARMA
KEYTRUDA+LENVIMA Approved in Japan for Radically Unresectable or Metastatic RCC
25 Feb 2022 //
BUSINESSWIRE
Lenvima fails to improve on Keytruda—again
15 Feb 2022 //
FIERCEPHARMA
KEYTRUDA + LENVIMA Approved in Japan in Endometrial Carcinoma
28 Dec 2021 //
BUSINESSWIRE
First patient dosed in the MIV-818 combination study
14 Dec 2021 //
PRNEWSWIRE
Merck, Eisai`s 007 study dies in 1L lung cancer
11 Dec 2021 //
FIERCEPHARMA
EC grants approval for Merck-Eisai’s combo therapy for endometrial cancer
30 Nov 2021 //
PHARMACEUTICAL-TECHNOLOGY
European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA®
29 Nov 2021 //
BUSINESSWIRE
Merck and Eisai Receive +ve EU CHMP Opinions for KEYTRUDA Plus LENVIMA in Cancer
15 Oct 2021 //
BUSINESSWIRE
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2021
14 Sep 2021 //
ACNNEWSWIRE
Medivir bags UK MHRA approval for phase 1/2a study of MIV-818 in liver cancer
02 Sep 2021 //
PHARMABIZ
MSD announce new data from advanced renal cell carcinoma trial
08 Jun 2021 //
PHARMAFILE
Data on Pembrolizumab+Lenvatinib From CLEAR/KEYNOTE-581 Trial Presented at ASCO
07 Jun 2021 //
BUSINESSWIRE
Eisai Data at ASCO 2021 Highlight Breadth of Oncology Portfolio Across Various
17 May 2021 //
PRNEWSWIRE
Eisai: European Medicines Agency Accepts the Marketing Authorisation
30 Mar 2021 //
ACNNEWSWIRE
Eisai`s Anti Cancer agent Lenvatinib-Pembrolizumab combo receives EMA in Japan
30 Mar 2021 //
BIOSPECTRUMASIA
Eisai`s Anti Cancer agent Lenvatinib-Pembrolizumab combo receives EMA in Japan
29 Mar 2021 //
BIOSPECTRUMASIA
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Significantly Improved
19 Mar 2021 //
BUSINESSWIRE
KEYTRUDA® (pembrolizumab) Plus LENVIMA® Significantly Improved Progression
19 Mar 2021 //
BUSINESSWIRE
Lenvatinib Plus Pembrolizumab Improves Survival, Responses Versus Sunitinib
15 Feb 2021 //
ONCLIVE
Eisai to Present Investigational Data on LENVIMA® (lenvatinib)
27 Jan 2021 //
PRNEWSWIRE
Eisai to Present Data on LENVIMA® Monotherapy and in Combination with KEYTRUDA®
11 Jan 2021 //
PRNEWSWIRE
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination
15 Dec 2020 //
MERCK
Eisai Announces New Investigational Data from Study 211
20 Nov 2020 //
PRNNEWSWIRE
Eisai Announces Investigational Data Highlighting LENVIMA® (lenvatinib)
05 Nov 2020 //
PRNEWSWIRE
Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150m
05 Nov 2020 //
PRESSRELEASE
BDR Pharma launches generic cancer drug in India
20 Oct 2020 //
ECONOMICTIMES
New Lenvima/Keytruda combo data in a range of cancers presented at ESMO 2020
21 Sep 2020 //
PHARMAFILE
Merck’s Keytruda® Reduced The Risk Of Death By 40%
20 Sep 2020 //
PRESS RELEASE
Scientific Data Reflects Mercks Commitment to Advance Cancer Research and Care
02 Sep 2020 //
PRESS RELEASE
EISAI ANNOUNCES TOPLINE RESULTS FROM STUDY 211 SUPPORTING 24 MG
11 Aug 2020 //
MEDIAROOM
Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab)
08 Jul 2020 //
BUSINESSWIRE
Eisai to Present Latest Data from Oncology Pipeline at ASCO 2020, KEYTRUDA®
13 May 2020 //
PRNEWSWIRE
Merck to Present New Data from its Broad Oncology Portfolio &Pipeline at ASCO20
07 May 2020 //
BUSINESSWIRE
Eisai Announces Latest Data for LENVIMA® in Combination with Everolimus
17 Feb 2020 //
PR NEWSWIRE
Shilpa Medicare Launches Breakthrough Therapy Lenvatinib Mesylate
03 Feb 2020 //
BUSINESS
